PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 254 filers reported holding PACIRA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.88 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,513,917 | -50.7% | 147,129 | -35.6% | 0.00% | -100.0% |
| Q2 2023 | $9,149,944 | +16.0% | 228,349 | +18.1% | 0.00% | -33.3% |
| Q1 2023 | $7,888,940 | +3758.8% | 193,309 | +3550.8% | 0.00% | – |
| Q4 2022 | $204,440 | -93.8% | 5,295 | -91.4% | 0.00% | – |
| Q3 2022 | $3,289,000 | +203.4% | 61,850 | +232.5% | 0.00% | – |
| Q2 2022 | $1,084,000 | -81.2% | 18,600 | -75.4% | 0.00% | -100.0% |
| Q1 2022 | $5,763,000 | +10.7% | 75,508 | -12.7% | 0.00% | – |
| Q4 2021 | $5,206,000 | +176.8% | 86,524 | +157.5% | 0.00% | – |
| Q3 2021 | $1,881,000 | -26.1% | 33,600 | -19.9% | 0.00% | – |
| Q2 2021 | $2,544,000 | -29.5% | 41,941 | -18.5% | 0.00% | – |
| Q1 2021 | $3,608,000 | -67.3% | 51,470 | -72.1% | 0.00% | – |
| Q4 2020 | $11,042,000 | +55.6% | 184,528 | +56.3% | 0.00% | -100.0% |
| Q3 2020 | $7,098,000 | +32.0% | 118,079 | +15.2% | 0.00% | 0.0% |
| Q2 2020 | $5,377,000 | +3.6% | 102,482 | -33.8% | 0.00% | -50.0% |
| Q1 2020 | $5,191,000 | +14.4% | 154,799 | +54.5% | 0.00% | +100.0% |
| Q4 2019 | $4,539,000 | +14.4% | 100,200 | -3.9% | 0.00% | 0.0% |
| Q3 2019 | $3,968,000 | -84.1% | 104,226 | -81.8% | 0.00% | -66.7% |
| Q2 2019 | $24,897,000 | +201.7% | 572,514 | +164.1% | 0.00% | -25.0% |
| Q1 2019 | $8,252,000 | -40.3% | 216,800 | -32.5% | 0.00% | -20.0% |
| Q4 2018 | $13,824,000 | +6.4% | 321,329 | +21.6% | 0.01% | +25.0% |
| Q3 2018 | $12,989,000 | +70.4% | 264,262 | +11.1% | 0.00% | +100.0% |
| Q2 2018 | $7,623,000 | +11.2% | 237,855 | +8.1% | 0.00% | 0.0% |
| Q1 2018 | $6,856,000 | -47.6% | 220,100 | -23.2% | 0.00% | -60.0% |
| Q4 2017 | $13,083,000 | +39.3% | 286,600 | +14.6% | 0.01% | +66.7% |
| Q3 2017 | $9,392,000 | +31.8% | 250,125 | +67.4% | 0.00% | 0.0% |
| Q2 2017 | $7,126,000 | -35.4% | 149,400 | -38.2% | 0.00% | -50.0% |
| Q1 2017 | $11,026,000 | -56.1% | 241,800 | -68.9% | 0.01% | -50.0% |
| Q4 2016 | $25,144,000 | +23.3% | 778,426 | +30.6% | 0.01% | +33.3% |
| Q3 2016 | $20,397,000 | +134.8% | 596,049 | +131.4% | 0.01% | +80.0% |
| Q2 2016 | $8,687,000 | -62.0% | 257,570 | -40.2% | 0.01% | -58.3% |
| Q1 2016 | $22,833,000 | -22.0% | 430,954 | +13.1% | 0.01% | -7.7% |
| Q4 2015 | $29,270,000 | +149.2% | 381,158 | +33.4% | 0.01% | +160.0% |
| Q3 2015 | $11,745,000 | -61.6% | 285,764 | -34.0% | 0.01% | -61.5% |
| Q2 2015 | $30,620,000 | -14.1% | 432,981 | +7.9% | 0.01% | -23.5% |
| Q1 2015 | $35,651,000 | +77.7% | 401,249 | +77.4% | 0.02% | +112.5% |
| Q4 2014 | $20,058,000 | -21.9% | 226,235 | -14.6% | 0.01% | -20.0% |
| Q3 2014 | $25,670,000 | +65.9% | 264,859 | +57.3% | 0.01% | +66.7% |
| Q2 2014 | $15,472,000 | +90.6% | 168,423 | +45.2% | 0.01% | +50.0% |
| Q1 2014 | $8,118,000 | -4.9% | 115,984 | -21.9% | 0.00% | 0.0% |
| Q4 2013 | $8,535,000 | +193.5% | 148,469 | +145.4% | 0.00% | +100.0% |
| Q3 2013 | $2,908,000 | +178.3% | 60,500 | +67.8% | 0.00% | – |
| Q2 2013 | $1,045,000 | – | 36,056 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |